Cancer Centers Report Fast Daraxonrasib Access Despite Billing Hurdles
Becker's Hospital Review reports that nearly three months after the FDA approved daraxonrasib for metastatic pancreatic cancer on Aug. 26, leaders at seven cancer centers say patients at academic and community sites are starting the drug within one to two weeks, faster than some in oncology expected. Wait times vary by site: UC San Diego Health reports five to seven days, UW Health's Carbone Cancer Center has dropped to three to seven days from 10 to 14 at launch, while Lowell General Hospital in the community setting reports three to four weeks, with insurance approval cited as the biggest bottleneck. Medicare approvals have moved quickly, while some commercial payers have required appeal letters from oncologists, according to UW Health pharmacist Elizabeth Dow-Hillgartner. The drug currently ships through a limited network of two specialty pharmacies, Onco360 and Biologics by McKesson, and Dow-Hillgartner said manufacturer Revolution Medicines has indicated it will open distribution to more specialty pharmacies.